Dual Marker is a screening test, not a diagnostic test. This test is based on a predictive and statistical approach, further testing is always needed to confirm a diagnosis.
*The accuracy of the results is subjective to the information provided in the screening form(Annexure – CR 02) and this information is mandatory for combined risk assessment
* For combined risk assessment, it is always advisable to get tested in 11-13 weeks of pregnancy.
What does Dual Marker Test Measure?
This test measures the levels of b-hCG and PAPP-A in blood with the ultrasound test. b-hCG is a hormone which is produced by the cells in the developing placenta during pregnancy. The levels of b-hCG increases in early pregnancy. The role of b-hCG in early pregnancy is to maintain the function of corpus luteum (the hormone-secreting structure that develops in an ovary). During the first three weeks production of b-hCG increases reaching to peak levels at 10th week (from the last menstrual cycle). After that, the levels of b-hCG start to fall to negligible within a few weeks after delivery.
PAPP-A is secreted by the placenta and its levels increase with duration of pregnancy. Variety of tissues express PAPP-A at very lower levels. Plaques which are not stable in coronary arteries also express PAPP-A in high levels.
Dual marker test is done along with Nuchal Translucency test to confirm the diagnosis of any genetic abnormality.
Nuchal Translucency (NT) is a measurement of the fluid beneath the skin along the back of the baby’s neck. NT is measured by ultrasonography.
Includes selection of all required tests, lab & time
Highly trained phlebotomist adhering to all COVID
Phlebotomist delivers your sample to lab
Reports are delivered on delivered on
Home sample pickup
Free doctor consultation
100% vaccinated phlebotomist
Trusted and certified labs
Download the Pre-treatment Checklist